Navigation Links
DelMar Pharmaceuticals Gives Quarterly Shareholder Update
Date:11/11/2013

.  Guangxi Wuzhou Pharmaceuticals will provide funding for clinical trials conducted in China and will be the exclusive supplier of VAL-083, and DelMar will be responsible for undertaking clinical development and commercialization activities.

We are continuing our efforts to secure a sales and marketing partner for VAL-083 in China. We are in discussions with potential partners who have who have significant experience marketing oncology products in the China marketplace and who could be valuable in helping to position VAL-083 within this market.  Our goal is to establish a sales and marketing relationship that will provide DelMar with ongoing royalty payments from sales in the China market.

We Are Attempting to Create Important New Medicines for Patients and Increased Value for Shareholders
On behalf of the entire DelMar Pharma team, I thank you for your continued support of our mission to develop and commercialize proven medicines for patients who have failed currently available therapy.  As always, our goal remains to serve patients who have unmet clinical needs and to build value for our shareholders in the timeliest manner possible.   

With warm personal regards,

Jeffrey A. Bacha
President and CEO
DelMar Pharmaceuticals

Twitter @DelMarPharma
Facebook.com/DelMarPharma

Safe Harbor Statement
Any statements contained in this update that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but a
'/>"/>

SOURCE DelMar Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. DelMar Pharmaceuticals Presents Data Supporting VAL-083 as a Potential Treatment for Three Chemotherapy Resistant Cancers
2. DelMar Pharma reviews glioblastoma clinical trials and new therapeutic development on CEOLIVE.TV
3. DelMar Pharmaceuticals and Guangxi Wuzhou Pharmaceuticals Establish Clinical Advisory Board in China
4. DelMar Pharmaceuticals To Present At The 15th Annual Rodman & Renshaw Global Investment Conference
5. DelMar Pharmaceuticals, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
6. DelMar Pharmaceuticals Presents Additional Clinical Data from Ongoing Brain Cancer Study at ASCO
7. DelMar Pharmaceuticals, Inc. to Webcast, Live, at RetailInvestorConferences.com June 6th
8. DelMar Pharmaceuticals to Present Clinical Trials Data for VAL-083 Brain Cancer Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting
9. DelMar Pharmaceuticals, Inc. Provides Corporate Update for the Quarter Ended March 31, 2013
10. DelMar Pharma Presents Encouraging Data From Ongoing Phase I/II GBM Clinical Trial With VAL-083
11. DelMar Pharmaceuticals to Present Clinical Data from VAL-083 Brain Cancer Trial at the American Association of Cancer Research Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)...  Research and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) has ... Market - Global Industry Analysis, Size, Share, Growth, ... to their offering. (Logo: ... are products which are used on patients in ... and in treatment of associated gingival tissues. This ...
(Date:1/15/2014)... -- Celsion Corporation (the "Company") (NASDAQ: CLSN ... from institutional investors to purchase an aggregate of ... in an at-the-market registered direct offering, led by ... Company entered into definitive purchase agreements with these ... sell an aggregate of 3,603,603 shares of its ...
(Date:1/15/2014)... January 15, 2014 BreedIT Corp ... exclusive worldwide distributor of highly sophisticated agro-breeding solutions for ... 7, 2014, the Company,s board of directors appointed chemistry ... as its new member of the board. ... with Teva Pharmaceutical Industries Ltd (NYSE: TEVA ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
... Endologix, Inc. (Nasdaq: ELGX ), developer and ... today that the first U.S. commercial implant of the ... Hines, Jr. VA Hospital in Chicago, IL. The procedure ... and Chief of Vascular Surgery & Endovascular Therapy at ...
... Britain,s best-loved comedienne and TV favourite Jo Brand has joined ... for a brand new comedy film (54 seconds) to launch ... film sees Jo Brand running around South London, in what ... her kitchen with Joanna Scanlan and produces a pint of ...
Cached Medicine Technology:Endologix Announces First U.S. Implant of AFX™ Endovascular AAA System 2TV Favourite Jo Brand Puts Her Best Foot Forward for Macmillan Cancer Support 2TV Favourite Jo Brand Puts Her Best Foot Forward for Macmillan Cancer Support 3
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... Synthetech, Inc. (OTC,Bulletin Board: NZYM) today announced that ... become Synthetech,s President and Chief Executive Officer. Since,September ... and Chief,Operating Officer. Dr. Hahn will replace as ... continue as Synthetech,s Chairman of the Board.,Synthetech intends ...
... Industrial Control Repair, Inc.,(ICR), headquartered in Warren, Michigan, ... their superior delivery of MRO Asset Management and,industrial ... asset management solutions and selling refurbished,industrial equipment to ... honor at the annual Honda of America Manufacturing,MRO ...
... it will be several years before there,s widespread use ... new imaging device could one day help doctors detect ... and more accurately, researchers report. , If left undetected ... or acute glaucoma attack, which can result in permanent ...
... and Other Providers Would Likely Demand Similar,Treatment Next Year, ... (PCMA) released a new ad today warning policymakers,that other ... demand the "same prompt-pay deal" next year if Congress ... Medicare., "Paying one group of Medicare providers twice ...
... NEW YORK, June 9 Officials with the U.S.,Fund ... Inc.,announced the donation and delivery of 100,000 doses of ... to the,government of the former Soviet republic of Moldova, ... country., The vaccine is a combination vaccine against ...
... more sleepy, restless and stressed , , MONDAY, June 9 ... cell phones may be placing their health at risk ... Swedish study suggests. , The finding was presented Monday ... Baltimore. , "The message is that adolescents who use ...
Cached Medicine News:Health News:Synthetech Announces Appointment of Dr. Gregory R. Hahn as President and Chief Executive Officer 2Health News:Synthetech Announces Appointment of Dr. Gregory R. Hahn as President and Chief Executive Officer 3Health News:Industrial Control Repair Named Honda of America Manufacturing's '2007 Supplier of the Year' 2Health News:New Imaging Tool Can Spot Glaucoma Risk 2Health News:New Imaging Tool Can Spot Glaucoma Risk 3Health News:New PCMA Ad: Pharmacist 'Prompt Pay' Will Trigger 'Domino Effect' Among Other Medicare Providers 2Health News:UNICEF & Merck Partner to Protect 100,000 Children and Young People Against Mumps Epidemic 2Health News:UNICEF & Merck Partner to Protect 100,000 Children and Young People Against Mumps Epidemic 3Health News:Too Much Cell Phone Time Takes Toll on Teen Sleep 2Health News:Too Much Cell Phone Time Takes Toll on Teen Sleep 3
Immuno-turbidimetric assay for Free Protein Sby STA© Analyzers. Suspension of microparticles coated with monoclonal antibodies to Free Protein S....
Colorimetric Assay of Unfractionated and Low Molecular Weight Heparins by STA© Analyzers. Lyophilized, patent-pending chromogenic substate, CBS 52.44 of ~4.2 moles/vial and bovine factor Xa ~1.1...
Substrate Plasma for Factor VII Assay by STA© Analyzers. Freeze-dried human plasma from which factor VII has been removed by selective immuno-adsorption....
Substrate Plasma for Factor IX Assay by STA© Analyzers. Freeze-dried human plasma from which factor IX has been removed by selective immuno-adsorption....
Medicine Products: